Belgium : New TREMFYA (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

Press/Media

Period27 Oct 2022 → 3 Nov 2022

Media coverage

3

Media coverage